Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights

LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the second quarter 2020.